Jules Grégory
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jules Grégory has a total of 323 co-authors. Here are the top co-authors by number of shared publications:
- Maxime Ronot
Université Paris Cité, France & Service de Radiologie, Hôpital Beaujon, APHP.Nord, Clichy, France
13 shared publications Valérie Vilgrain
Department of Radiology, CRI Inserm 1149, Université Paris Cité, FHU MOSAIC², AP-HP Hôpital Beaujon, Clichy, France
13 shared publicationsMaxime Ronot
Department of Radiology, CRI Inserm 1149, Université Paris Cité, FHU MOSAIC², AP-HP Hôpital Beaujon, Clichy, France
8 shared publications- Valérie Vilgrain
Department of Radiology, Hôpital Beaujon, AP-HP.Nord, Clichy, France
6 shared publications Souhail Bennani
Université de Paris, APHP, Hôpital Cochin, Dept of Radiology, Paris, France
4 shared publicationsChristophe Aubé
CHU Angers, Department of Radiology, Laboratoire HIFIH UPRES 3859, SFR ICAT 4208, Angers University, Angers, France
3 shared publications
Latest Publications
- Open Access
Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC)
Introduction: Primary liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, are one of the leading causes of cancer-related mortality. Transarterial chemoembolisation (TACE) and radioembolisation (TARE) are established palliative treatments yet they are traditionally performed during inpatient hospitalisation. Recent technical and organisational advances allow for safe same-day ambulatory procedures. In particular, the extent to which ambulatory intra-arterial therapy aligns with patients’ expectations, comfort and quality of life remains poorly documented. The Care pathway for Hepatic intra-arterial Oncology in an ambulatory Context study (CHOC) trial aims to evaluate the implementation and effectiveness from both patient-centred and clinical perspectives of an ambulatory care pathway for intra-arterial treatment of primary liver cancer in a multicentre randomised hybrid type 1 trial. Methods and analysis: CHOC is a pragmatic, multicentre, randomised controlled hybrid type 1 trial comparing ambulatory versus conventional inpatient care for patients undergoing TACE or TARE for primary liver cancer. A total of 206 patients (103 per arm) will be randomised 1:1 and followed for 7 months. The primary outcome is the patient’s global satisfaction score, measured 3 days post-procedure using the EORTC PATSAT-C33 questionnaire. Secondary outcomes include quality of life, safety, clinical outcomes, cost analysis and an embedded qualitative implementation study assessing acceptability, adoption, feasibility and sustainability across centres. Economic analyses will estimate both per-patient costs and the 5-year budget impact for the French national health insurance. Ethics and dissemination: The study has received ethical approval from the Protection of Persons Committee and adheres to the Declaration of Helsinki, good clinical practice and French regulatory requirements. Findings will be disseminated through peer-reviewed publications, conferences and participating centres to guide broader implementation of ambulatory interventional radiology care. Trial registration number: NCT06990659 .
Open AccessImplementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC)
Introduction: Primary liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, are one of the leading causes of cancer-related mortality. Transarterial chemoembolisation (TACE) and radioembolisation (TARE) are established palliative treatments yet they are traditionally performed during inpatient hospitalisation. Recent technical and organisational advances allow for safe same-day ambulatory procedures. In particular, the extent to which ambulatory intra-arterial therapy aligns with patients’ expectations, comfort and quality of life remains poorly documented. The Care pathway for Hepatic intra-arterial Oncology in an ambulatory Context study (CHOC) trial aims to evaluate the implementation and effectiveness from both patient-centred and clinical perspectives of an ambulatory care pathway for intra-arterial treatment of primary liver cancer in a multicentre randomised hybrid type 1 trial. Methods and analysis: CHOC is a pragmatic, multicentre, randomised controlled hybrid type 1 trial comparing ambulatory versus conventional inpatient care for patients undergoing TACE or TARE for primary liver cancer. A total of 206 patients (103 per arm) will be randomised 1:1 and followed for 7 months. The primary outcome is the patient’s global satisfaction score, measured 3 days post-procedure using the EORTC PATSAT-C33 questionnaire. Secondary outcomes include quality of life, safety, clinical outcomes, cost analysis and an embedded qualitative implementation study assessing acceptability, adoption, feasibility and sustainability across centres. Economic analyses will estimate both per-patient costs and the 5-year budget impact for the French national health insurance. Ethics and dissemination: The study has received ethical approval from the Protection of Persons Committee and adheres to the Declaration of Helsinki, good clinical practice and French regulatory requirements. Findings will be disseminated through peer-reviewed publications, conferences and participating centres to guide broader implementation of ambulatory interventional radiology care. Trial registration number: NCT06990659 .
- Open Access
- 15 June 2026
- Published by Elsevier in Journal d'imagerie diagnostique et interventionnelle
- Vol. 9 (5) , 227-233
Recommandations de la Société d’imagerie abdominale et digestive pour l’utilisation des produits de contraste iodés en tomodensitométrie abdominale et digestive : protocoles selon l’indication et optimisation des volumes
- 15 June 2026
- Published by Elsevier in Journal d'imagerie diagnostique et interventionnelle
- Vol. 9 (5) , 227-233
Open AccessRecommandations de la Société d’imagerie abdominale et digestive pour l’utilisation des produits de contraste iodés en tomodensitométrie abdominale et digestive : protocoles selon l’indication et optimisation des volumes
- Open Access
- 20 May 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (8) , 101900
Combining MRI criterion and pathology-based microvascular invasion improves prognostic stratification in early HCC
- 20 May 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (8) , 101900
Open AccessCombining MRI criterion and pathology-based microvascular invasion improves prognostic stratification in early HCC
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Biais et spécificités méthodologiques des essais contrôlés randomisés en radiologie interventionnelle : l’exemple des traitements du carcinome hépatocellulaire
La méthodologie de l'essai contrôlé randomisé (ECR) a été utilisée pour la première fois en radiologie interventionnelle (RI) en 1985 dans un essai évaluant la chimioembolisation intraartérielle hépatique (CEH) pour le traitement du carcinome hépatocellulaire (CHC). La spécialité a progressivement adopté cette méthode d'évaluation pour les nouveaux traitements et les innovations techniques. Pourtant, l’application de cette méthodologie à la RI pose, comme pour d’autres traitements non pharmacologiques (TNP), des questions méthodologiques spécifiques liées à la complexité des interventions, à l'influence de l’opérateur, à l'expertise du centre et aux difficultés de l'aveugle, qui ont une influence majeure sur la planification, mise en œuvre et l'interprétation des ECR. Dans un premier projet, nous avons évalué dans quelle mesure les résultats des ECR enregistrés évaluant la CEH pour le traitement du CHC étaient publiquement accessibles. Parmi les 67 ECR identifiés, représentant un nombre total de 11 599 patients, près des deux tiers n'ont donné lieu à aucun résultat public, que ce soit sur la plateforme du registre ou dans une revue scientifique. La sous-déclaration des résultats des essais est une cause majeure de gaspillage de la recherche médicale, car les résultats de recherche inaccessibles n'aident ni les patients ni les cliniciens. Dans un second projet, nous avons déterminé la proportion d’ECR évaluant la CEH pour le CHC et publiés après 2007 qui étaient enregistrés. Nous avons comparé les critères de jugements principaux enregistrés avec ceux rapportés dans les publications afin de déterminer si le biais de mention favorisait les résultats significatifs. Nous avons constaté que la moitié de ces ECR publiés n'étaient pas enregistrés, et que lorsqu'ils l'étaient, un tiers d'entre eux présentaient des discordances importantes entre les critères de jugements principaux enregistrés et publiés. Un biais de mention sélectif favorisant les résultats de l'essai était observé dans 7% des ECR publiés. Dans un troisième projet, nous avons évalué l'exhaustivité du reporting des résumés dans les ECR pour la RI hépatique et l'impact de la publication de l'extension CONSORT 2017 pour le TNP. Nous avons aussi évalué la tendance d'évolution dans le temps à l'aide d'une analyse de séries chronologiques. Nous avons constaté que l'exhaustivité des rapports était faible dans les résumés d'essais pour la RI hépatique et qu’elle ne s'est pas améliorée après la publication de la déclaration CONSORT-TNP. Dans le cadre d'un quatrième projet, nous avons travaillé sur la radiothérapie interne sélective du CHC et développé un textbook outcome afin de proposer un outil de standardisation complet, adapté aux soins et à la recherche, dédié au déroulé de l’intervention. Cette étude s'est déroulée en deux étapes : (1) le comité de pilotage a d'abord dressé une liste exhaustive d’items candidats à refléter les composantes de l’intervention radiothérapie interne sélective RIS sur la base d'une analyse de la littérature, (2) puis a mené une enquête internationale et multidisciplinaire qui a abouti au textbook outcome final. Ce textbook outcome final se compose de 11 items répartis sur six domaines correspondant aux différentes étapes de la radiothérapie interne sélective et reflétant une intervention idéale. Tous ces items, sauf un, étaient appliqués dans les institutions de plus de 80 % des experts ayant participé à l’élaboration du textbook outcome. Notre travail fournit des domaines d'amélioration pour les ECR sur la RI à travers 1) l’accessibilité des résultats des essais afin de réduire le gaspillage de la recherche ; 2) l'enregistrement prospectif des essais pour assurer la qualité et la transparence ; 3) l'amélioration du reporting des essais avec des résumés décrivant les spécificités des interventions non-pharmacologiques; et 4) la standardisation des interventions via un outil capturant leurs dimensions essentielles.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Biais et spécificités méthodologiques des essais contrôlés randomisés en radiologie interventionnelle : l’exemple des traitements du carcinome hépatocellulaire
La méthodologie de l'essai contrôlé randomisé (ECR) a été utilisée pour la première fois en radiologie interventionnelle (RI) en 1985 dans un essai évaluant la chimioembolisation intraartérielle hépatique (CEH) pour le traitement du carcinome hépatocellulaire (CHC). La spécialité a progressivement adopté cette méthode d'évaluation pour les nouveaux traitements et les innovations techniques. Pourtant, l’application de cette méthodologie à la RI pose, comme pour d’autres traitements non pharmacologiques (TNP), des questions méthodologiques spécifiques liées à la complexité des interventions, à l'influence de l’opérateur, à l'expertise du centre et aux difficultés de l'aveugle, qui ont une influence majeure sur la planification, mise en œuvre et l'interprétation des ECR. Dans un premier projet, nous avons évalué dans quelle mesure les résultats des ECR enregistrés évaluant la CEH pour le traitement du CHC étaient publiquement accessibles. Parmi les 67 ECR identifiés, représentant un nombre total de 11 599 patients, près des deux tiers n'ont donné lieu à aucun résultat public, que ce soit sur la plateforme du registre ou dans une revue scientifique. La sous-déclaration des résultats des essais est une cause majeure de gaspillage de la recherche médicale, car les résultats de recherche inaccessibles n'aident ni les patients ni les cliniciens. Dans un second projet, nous avons déterminé la proportion d’ECR évaluant la CEH pour le CHC et publiés après 2007 qui étaient enregistrés. Nous avons comparé les critères de jugements principaux enregistrés avec ceux rapportés dans les publications afin de déterminer si le biais de mention favorisait les résultats significatifs. Nous avons constaté que la moitié de ces ECR publiés n'étaient pas enregistrés, et que lorsqu'ils l'étaient, un tiers d'entre eux présentaient des discordances importantes entre les critères de jugements principaux enregistrés et publiés. Un biais de mention sélectif favorisant les résultats de l'essai était observé dans 7% des ECR publiés. Dans un troisième projet, nous avons évalué l'exhaustivité du reporting des résumés dans les ECR pour la RI hépatique et l'impact de la publication de l'extension CONSORT 2017 pour le TNP. Nous avons aussi évalué la tendance d'évolution dans le temps à l'aide d'une analyse de séries chronologiques. Nous avons constaté que l'exhaustivité des rapports était faible dans les résumés d'essais pour la RI hépatique et qu’elle ne s'est pas améliorée après la publication de la déclaration CONSORT-TNP. Dans le cadre d'un quatrième projet, nous avons travaillé sur la radiothérapie interne sélective du CHC et développé un textbook outcome afin de proposer un outil de standardisation complet, adapté aux soins et à la recherche, dédié au déroulé de l’intervention. Cette étude s'est déroulée en deux étapes : (1) le comité de pilotage a d'abord dressé une liste exhaustive d’items candidats à refléter les composantes de l’intervention radiothérapie interne sélective RIS sur la base d'une analyse de la littérature, (2) puis a mené une enquête internationale et multidisciplinaire qui a abouti au textbook outcome final. Ce textbook outcome final se compose de 11 items répartis sur six domaines correspondant aux différentes étapes de la radiothérapie interne sélective et reflétant une intervention idéale. Tous ces items, sauf un, étaient appliqués dans les institutions de plus de 80 % des experts ayant participé à l’élaboration du textbook outcome. Notre travail fournit des domaines d'amélioration pour les ECR sur la RI à travers 1) l’accessibilité des résultats des essais afin de réduire le gaspillage de la recherche ; 2) l'enregistrement prospectif des essais pour assurer la qualité et la transparence ; 3) l'amélioration du reporting des essais avec des résumés décrivant les spécificités des interventions non-pharmacologiques; et 4) la standardisation des interventions via un outil capturant leurs dimensions essentielles.
- 5 December 2025
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 107 (1) , 5-6
Beyond algorithms: How agent-based artificial intelligence is changing the future of radiology
- 5 December 2025
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 107 (1) , 5-6
Beyond algorithms: How agent-based artificial intelligence is changing the future of radiology
- 11 June 2025
- Published by Societe de Reanimation de Langue Francaise in Médecine Intensive Réanimation
- Vol. 34 (Hors-série)
Imagerie hépatique en soins critiques
Le foie joue un rôle central dans l’homéostasie et est particulièrement vulnérable aux agressions rencontrées en soins critiques. L’imagerie hépatique, en particulier l’échographie-Doppler et le scanner, est essentielle pour la prise en charge des patients. Cet article explore les principaux aspects de l’imagerie hépatique en soins critiques selon quatre axes. Tout d’abord, des éléments de radioanatomie, de vascularisation et de physiologique du foie sont discutés. Ensuite, les atteintes hépatiques secondaires aux pathologies systémiques, comme les états de choc, l’hépatopathie congestive ou les pathologies infectieuses, sont détaillées. Les pathologies hépatiques intrinsèques, notamment la cirrhose et les tumeurs hépatiques, également fréquentes en soins intensifs sont ensuite abordées. Enfin, la connaissance des grands aspects de l’imagerie post-thérapeutique chirurgicale et endovasculaires fait également de l’approche globale de l’imagerie hépatique en réanimation. L’objectif de cette revue est de donner les clés pour l’interprétation de l’imagerie hépatique de réanimation, abordant d’abord normal et les conditions pathologiques les plus fréquemment observées en soins critiques.
- 11 June 2025
- Published by Societe de Reanimation de Langue Francaise in Médecine Intensive Réanimation
- Vol. 34 (Hors-série)
Imagerie hépatique en soins critiques
Le foie joue un rôle central dans l’homéostasie et est particulièrement vulnérable aux agressions rencontrées en soins critiques. L’imagerie hépatique, en particulier l’échographie-Doppler et le scanner, est essentielle pour la prise en charge des patients. Cet article explore les principaux aspects de l’imagerie hépatique en soins critiques selon quatre axes. Tout d’abord, des éléments de radioanatomie, de vascularisation et de physiologique du foie sont discutés. Ensuite, les atteintes hépatiques secondaires aux pathologies systémiques, comme les états de choc, l’hépatopathie congestive ou les pathologies infectieuses, sont détaillées. Les pathologies hépatiques intrinsèques, notamment la cirrhose et les tumeurs hépatiques, également fréquentes en soins intensifs sont ensuite abordées. Enfin, la connaissance des grands aspects de l’imagerie post-thérapeutique chirurgicale et endovasculaires fait également de l’approche globale de l’imagerie hépatique en réanimation. L’objectif de cette revue est de donner les clés pour l’interprétation de l’imagerie hépatique de réanimation, abordant d’abord normal et les conditions pathologiques les plus fréquemment observées en soins critiques.
- 10 March 2025
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 106 (6) , 237-238
Artificial intelligence in radiology reports: Is it the pen or the author?
- 10 March 2025
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 106 (6) , 237-238
Artificial intelligence in radiology reports: Is it the pen or the author?
- Open Access
- 17 February 2025
- Published by Springer Nature in Insights into Imaging
- Vol. 16 (1) , 1-11
Assessing the perceived impact of ESOR training programs on radiologists’ professional development
Objectives: This study evaluates the perceived impact of European School of Radiology (ESOR) training programs on radiologists’ professional development. Methods: A cross-sectional survey targeted alumni who participated in ESOR fellowships from 2011 to 2023. The survey included questions on demographics, professional background, ESOR program details, and career impact. Data were collected via a web-based questionnaire and analyzed using descriptive statistics and thematic analysis. Results: A total of 916 alumni were invited to the survey, with a response rate of 21% (190 participants). The median age was 31 years (range 29–33), and 54% were female. Most worked in public healthcare (62%) and were involved in academic activities (24%). Fellowship types included the visiting scholarship program (44%), Bracco fellowship (32%), and exchange program for fellowships (25%). The majority (59%) reported the fellowship helped them reach their current position, and 35% noted it upgraded their CV. Significant application of learned skills was reported by 69%. Ongoing cooperation with former tutors was maintained by 54%. Financial support was crucial, with 41% stating they could not have completed the training without it, 33% considering it very important, and 13% important. Participants rated the impact on clinical skills with a median score of 9/10. Other areas of impact included research skills (median 7/10), subspecialization (median 9/10), exposure to diverse practices (median 9/10), networking (median 10/10), and personal and professional growth (median 10/10). Conclusion: ESOR training programs significantly enhance radiologists’ professional development through comprehensive support, high-quality training, and substantial financial aid, ensuring participants are well-equipped for career advancement. Critical relevance statement: This study evaluates the perceived impact of ESOR training programs on radiologists’ professional development, highlighting significant enhancements in clinical skills, career advancement, and the critical role of financial support in facilitating access to high-quality education. Key Points: The ESOR offers various programs addressing both foundational and advanced training in radiology. Fifty-nine percent of participants reported that ESOR fellowships helped them achieve their current positions. Participants experienced a median improvement score of 9 out of 10 in clinical skills. Fifty-four percent of participants maintained ongoing cooperation with former tutors post-fellowship. ESOR financial support was perceived as crucial by many participants, ensuring access to high-quality education. Graphical
- 17 February 2025
- Published by Springer Nature in Insights into Imaging
- Vol. 16 (1) , 1-11
Open AccessAssessing the perceived impact of ESOR training programs on radiologists’ professional development
Objectives: This study evaluates the perceived impact of European School of Radiology (ESOR) training programs on radiologists’ professional development. Methods: A cross-sectional survey targeted alumni who participated in ESOR fellowships from 2011 to 2023. The survey included questions on demographics, professional background, ESOR program details, and career impact. Data were collected via a web-based questionnaire and analyzed using descriptive statistics and thematic analysis. Results: A total of 916 alumni were invited to the survey, with a response rate of 21% (190 participants). The median age was 31 years (range 29–33), and 54% were female. Most worked in public healthcare (62%) and were involved in academic activities (24%). Fellowship types included the visiting scholarship program (44%), Bracco fellowship (32%), and exchange program for fellowships (25%). The majority (59%) reported the fellowship helped them reach their current position, and 35% noted it upgraded their CV. Significant application of learned skills was reported by 69%. Ongoing cooperation with former tutors was maintained by 54%. Financial support was crucial, with 41% stating they could not have completed the training without it, 33% considering it very important, and 13% important. Participants rated the impact on clinical skills with a median score of 9/10. Other areas of impact included research skills (median 7/10), subspecialization (median 9/10), exposure to diverse practices (median 9/10), networking (median 10/10), and personal and professional growth (median 10/10). Conclusion: ESOR training programs significantly enhance radiologists’ professional development through comprehensive support, high-quality training, and substantial financial aid, ensuring participants are well-equipped for career advancement. Critical relevance statement: This study evaluates the perceived impact of ESOR training programs on radiologists’ professional development, highlighting significant enhancements in clinical skills, career advancement, and the critical role of financial support in facilitating access to high-quality education. Key Points: The ESOR offers various programs addressing both foundational and advanced training in radiology. Fifty-nine percent of participants reported that ESOR fellowships helped them achieve their current positions. Participants experienced a median improvement score of 9 out of 10 in clinical skills. Fifty-four percent of participants maintained ongoing cooperation with former tutors post-fellowship. ESOR financial support was perceived as crucial by many participants, ensuring access to high-quality education. Graphical
- Open Access
- 3 January 2025
- Published by Oxford University Press (OUP) in BJR|Artificial Intelligence
- Vol. 2 (1)
CT-based deep learning prediction of complete response in intermediate-stage hepatocellular carcinoma treated with drug-eluting beads transarterial chemoembolization
Objectives: To develop a CT-based deep learning (DL) model to predict complete response (CR) to drug-eluting beads-transarterial chemoembolization (TACE) in patients with naive Barcelona Clinic Liver Cancer (BCLC) B hepatocellular carcinoma (HCC). Methods: This dual-centre retrospective study included 93 patients with BCLC B HCC treated with drug-eluting beads-TACE (median size of 40 mm and 37 mm at Institutions 1 and 2). Complete response was defined as per modified Response Evaluation Criteria in Solid Tumours on liver contrast-enhanced CT within 2 months of treatment. A twin-network DL model with spatio-temporal Video Vision Transformer (ViViT) architecture was developed to predict CR using baseline dedicated liver CT. The model was extensively trained/tested based on an 8-fold cross-validation approach with an ensemble technique, a model vote system where the outcome is the average of multiple model predictions. Results: The CR rate was 36% (18/50) and 22% (11/49) at Institutions 1 and 2. The model showed high specificity and AUC, as well as moderate sensitivity and balanced accuracy when using either the late arterial phase (0.91 ± 0.12, 0.86 ± 0.16, 0.43 ± 0.23, and 0.67 ± 0.13, respectively) or the portal venous phase (0.90 ± 0.15, 0.85 ± 0.17, 0.57 ± 0.30, and 0.74 ± 0.16, respectively). Conclusion: The developed CT-based DL model predicted CR to drug-eluting beads-TACE in patients with naive BCLC B HCC with high specificity. It should be refined to improve sensitivity. Advances in knowledge: The study underscores the potential of artificial intelligence in precision medicine in patients with HCC. While the model shows promise, further research with larger datasets and prospective studies is needed to enhance its predictive power and clinical applicability.
- 3 January 2025
- Published by Oxford University Press (OUP) in BJR|Artificial Intelligence
- Vol. 2 (1)
Open AccessCT-based deep learning prediction of complete response in intermediate-stage hepatocellular carcinoma treated with drug-eluting beads transarterial chemoembolization
Objectives: To develop a CT-based deep learning (DL) model to predict complete response (CR) to drug-eluting beads-transarterial chemoembolization (TACE) in patients with naive Barcelona Clinic Liver Cancer (BCLC) B hepatocellular carcinoma (HCC). Methods: This dual-centre retrospective study included 93 patients with BCLC B HCC treated with drug-eluting beads-TACE (median size of 40 mm and 37 mm at Institutions 1 and 2). Complete response was defined as per modified Response Evaluation Criteria in Solid Tumours on liver contrast-enhanced CT within 2 months of treatment. A twin-network DL model with spatio-temporal Video Vision Transformer (ViViT) architecture was developed to predict CR using baseline dedicated liver CT. The model was extensively trained/tested based on an 8-fold cross-validation approach with an ensemble technique, a model vote system where the outcome is the average of multiple model predictions. Results: The CR rate was 36% (18/50) and 22% (11/49) at Institutions 1 and 2. The model showed high specificity and AUC, as well as moderate sensitivity and balanced accuracy when using either the late arterial phase (0.91 ± 0.12, 0.86 ± 0.16, 0.43 ± 0.23, and 0.67 ± 0.13, respectively) or the portal venous phase (0.90 ± 0.15, 0.85 ± 0.17, 0.57 ± 0.30, and 0.74 ± 0.16, respectively). Conclusion: The developed CT-based DL model predicted CR to drug-eluting beads-TACE in patients with naive BCLC B HCC with high specificity. It should be refined to improve sensitivity. Advances in knowledge: The study underscores the potential of artificial intelligence in precision medicine in patients with HCC. While the model shows promise, further research with larger datasets and prospective studies is needed to enhance its predictive power and clinical applicability.
- 19 December 2024
- Published by Springer Nature in European Radiology
- Vol. 35 (6) , 3181-3191
Prognostic value of early response in predicting survival in hepatocellular carcinoma patients treated with selective internal radiation therapy
Objectives This study evaluates the prognostic value of tumor response on CT at 3 months, assessed by Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), and Liver Imaging Reporting and Data System Treatment Response Algorithm (LR-TRA) in patients with hepatocellular carcinoma (HCC) treated with selective internal radiation therapy (SIRT). Materials and methods A retrospective analysis was conducted on 102 HCC patients treated with SIRT between 2018 and 2020. RECIST, mRECIST, and LR-TRA were assessed at 3 months post-SIRT. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan–Meier analysis and Cox proportional-hazards models. Results The median age was 71 years, and most patients (90%) had advanced-stage tumors (Barcelona Clinic Liver Cancer-C). After a median follow-up of 32.0 months (95% CI: 16.8–60.9), 60/102 patients died (59%), and 90/102 patients showed tumor progression (88%). Median OS was 20.4 months (95% CI: 15.4–33.0), and median PFS was 14.5 months (95% CI: 6.5–24.5); 1-year OS and PFS rates were 65.6% and 50.7%. Multivariable analysis revealed that early response according to RECIST 1.1 (HR 1.66, p = 0.30), mRECIST (HR 1.40, p = 0.215), and LR-TRA (HR 0.67, p = 0.30) were not predictors of OS. Disease progression evaluated by RECIST (HR 2.55, p < 0.001) and mRECIST (HR 2.53, p < 0.001), bilirubin levels (HR 1.03, p < 0.001), and prothrombin time (HR 0.98, p = 0.005) were predictors of OS. For PFS, neither RECIST nor mRECIST response, disease progression, nor LR-TRA viability were predictors. Conclusion In this advanced-stage HCC population, early response assessed by RECIST, mRECIST, and LR-TRA criteria did not predict OS or PFS after SIRT. However, early disease progression and liver function indicators were prognostic factors for OS. Key Points QuestionHow well does early tumor response, assessed at 3 months post-selective internal radiation therapy (SIRT), predict survival in advanced hepatocellular carcinoma (HCC) patients? Findings Early response, assessed by RECIST, mRECIST, and LR-TRA, did not predict overall or progression-free survival; disease progression and liver function indicators were significant predictors. Clinical relevance This study highlights the limitations of early imaging criteria in predicting survival outcomes in advanced HCC post-SIRT, suggesting the need for alternative or complementary prognostic indicators to guide treatment decisions.
- 19 December 2024
- Published by Springer Nature in European Radiology
- Vol. 35 (6) , 3181-3191
Prognostic value of early response in predicting survival in hepatocellular carcinoma patients treated with selective internal radiation therapy
Objectives This study evaluates the prognostic value of tumor response on CT at 3 months, assessed by Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), and Liver Imaging Reporting and Data System Treatment Response Algorithm (LR-TRA) in patients with hepatocellular carcinoma (HCC) treated with selective internal radiation therapy (SIRT). Materials and methods A retrospective analysis was conducted on 102 HCC patients treated with SIRT between 2018 and 2020. RECIST, mRECIST, and LR-TRA were assessed at 3 months post-SIRT. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan–Meier analysis and Cox proportional-hazards models. Results The median age was 71 years, and most patients (90%) had advanced-stage tumors (Barcelona Clinic Liver Cancer-C). After a median follow-up of 32.0 months (95% CI: 16.8–60.9), 60/102 patients died (59%), and 90/102 patients showed tumor progression (88%). Median OS was 20.4 months (95% CI: 15.4–33.0), and median PFS was 14.5 months (95% CI: 6.5–24.5); 1-year OS and PFS rates were 65.6% and 50.7%. Multivariable analysis revealed that early response according to RECIST 1.1 (HR 1.66, p = 0.30), mRECIST (HR 1.40, p = 0.215), and LR-TRA (HR 0.67, p = 0.30) were not predictors of OS. Disease progression evaluated by RECIST (HR 2.55, p < 0.001) and mRECIST (HR 2.53, p < 0.001), bilirubin levels (HR 1.03, p < 0.001), and prothrombin time (HR 0.98, p = 0.005) were predictors of OS. For PFS, neither RECIST nor mRECIST response, disease progression, nor LR-TRA viability were predictors. Conclusion In this advanced-stage HCC population, early response assessed by RECIST, mRECIST, and LR-TRA criteria did not predict OS or PFS after SIRT. However, early disease progression and liver function indicators were prognostic factors for OS. Key Points QuestionHow well does early tumor response, assessed at 3 months post-selective internal radiation therapy (SIRT), predict survival in advanced hepatocellular carcinoma (HCC) patients? Findings Early response, assessed by RECIST, mRECIST, and LR-TRA, did not predict overall or progression-free survival; disease progression and liver function indicators were significant predictors. Clinical relevance This study highlights the limitations of early imaging criteria in predicting survival outcomes in advanced HCC post-SIRT, suggesting the need for alternative or complementary prognostic indicators to guide treatment decisions.